Accuray Inc (ARAY) – Nasdaq

1 post / 0 neu
26.08.2009 11:05
#1
Bild des Benutzers Lupi
Offline
Kommentare: 487
Accuray Inc (ARAY) – Nasdaq

Ich bin gestern auf diese Firma gestossen, da die Aktie gestern um 12.50% eingebüsst hat. Accuray produziert das sogennante CyberKnife® basierend auf robotic systhem technology zur präzisen Bestrahlung von Tummoren, einzigartig weltweit.

Die haben gestern mit dem Q2 Resultat die Erwartungen nicht erfüllen können, gewisse Bestellungen wurden cancelled oder gestoppt und dies kann einige Monate mit sich ziehen bis im 2010, was dem aktuellen Wirtschaftsumfeld zuzuschreiben ist. Die Einnahmen bestehen hauptsächlich aus den Verkäufen des CyberKnifes aber auch aus Software und Wartung des Produktes.

Ich denke die Aktie hat einiges Aufholpotenzial, die Firma ist schuldenfrei und hat vor allem ein vielversprechendes Produkt (science-fiction becomes real :shock: ). Die Konjuktur wird sich weiterhin bessern und Kunden wie zum Beispiel Spitäler werden mit der Zeit wieder mehr an Budget erhalten. Die Firma ist stets auf einer guten Wachstumskurve:

"In a year of macro economic headwinds, we are pleased with our double digit revenue growth," said Euan S. Thomson, Ph.D., Accuray's president and chief executive officer. "As the momentum in CyberKnife System installations continues, an increasing number of cancer patients around the world are benefiting from full body radiosurgery treatment."

Outlook

The following statement is forward-looking and actual results may differ materially. During fiscal year 2010 Accuray expects revenue to be in the range of $215 to $230 million. CyberKnife system revenue, which represents over 70% of total revenue, is driven by customer installation schedules. Based on current customer schedules, revenue in the first quarter is expected to be low, in the range of $40 to $50 million. Revenue related to systems sold and installed in prior years under Platinum contracts is recognized over the term of the original service contract, generally 5 years. Revenue from Platinum contracts is expected to decline by approximately $38 million in fiscal 2010 from fiscal 2009. All other revenue is expected to grow by approximately $20 to $30 million.

About the CyberKnife(®) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY - News), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 70,000 patients worldwide and currently 176 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Aufklappen
"Die Hausse wird in der Baisse geboren, sie wächst in der Skepsis, altert im Optimismus und stirbt in der Euphorie."